Pfizer collaborates with BioNTech to develop coronavirus vaccine
By Nikita Chaurasia  Date: 2020-03-17

Pfizer collaborates with BioNTech to develop coronavirus vaccine

Increasing numbers of coronavirus cases worldwide have prompted researchers to develop a potential vaccine candidate to treat COVID-19 patients. Pfizer Inc., one of the leading American pharmaceutical companies, has reportedly collaborated with BioNTech SE, an immunotherapy organization pioneering novel therapies for cancer and other serious diseases, to further this cause.

Sources cite that both the companies have agreed to a LOI (letter of intent) regarding the co-development and distribution of potential mRNA-based vaccines for the treatment of COVID-19. The companies have also inked material transfer and collaboration agreements to facilitating immediate working. 

Mikael Dolsten, President and Chief Scientific Officer, Worldwide Research, Development & Medical, Pfizer, said that the company’s successful and on-going relationship with BioNTech gives both the firms the resiliency to mobilize combined resources with exceptional speed in the face of this global challenge.

Integrating Pfizer’s regulatory, development and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise would strengthen their company’s commitment to combatting this increasing pandemic as soon as possible.

Ugur Sahin, CEO and Co-Founder of BioNTech, said that this global pandemic demands for a worldwide effort. With this collaboration, BioNTech believes that it can fuel efforts to bring a COVID-19 vaccine for treating people across the globe.

Moreover, the two companies expects to leverage several research and development sites, including that in the U.S and Germany, to house the actions identified by the collaboration agreement.

Reliable reports claim that BioNTech and Pfizer are expected to team up quickly and finalize the conditions of the agreement such as financial terms, manufacturing, potential commercialization, and development activities over the next few weeks.

Meanwhile, on March 13, 2020, Pfizer declared a five-point plan calling on the biopharmaceutical companies to join the organization in committing to extraordinary collaboration to tackle COVID-19.

Source Credit - https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
By Nikita Chaurasia

San Francisco based digital currency exchange major Coinbase has reportedly announced its acquisition of the crypto prime brokerage platform, Tagomi. For eight years, Coinbase has been known for its credibility in the field of industry-leading tradin...

National Congress of China recommends government-led blockchain fund
National Congress of China recommends government-led blockchain fund
By Nikita Chaurasia

The parliament of China, National People’s Congress, has reportedly given a suggestion for a blockchain development fund, backed by the government to be able to build up a good governance system. The most powerful and important political adviso...

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
By Nikita Chaurasia

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial fo...

Researchers to investigate the risk of airborne viruses in buildings
Researchers to investigate the risk of airborne viruses in buildings
By Nikita Chaurasia

As the world gradually paces back to normalcy after recuperating from the devastating effects of COVID-19, a research team from DOE’s Lawrence Berkeley National Laboratory (Berkeley Lab) embarked on the quest to study the risk of airborne virus...

NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
By Nikita Chaurasia

NZME, a News Zealand media giant, has recently unveiled a symbolic US$0.61 (NZ$1) takeover bid for rival Stuff Limited in an attempt for consolidation of the news industry in the country, amid the downturn caused by the coronavirus pandemic. Nine Ent...